STOCKS TELEGRAPH

Tag: XBIO STOCK PRICE

  • Why Did Xenetic Biosciences (XBIO) Stock Lost 10% In Extended Trades?

    The share price of Xenetic Biosciences Inc. (XBIO) was down -9.78% in after-hours trading at $2.86. The XBIO stock closed last session at $3.17, an increase of 4.62% or $0.14. The Xenetic Biosciences traded between $2.56 and $3.72 throughout the day. The number of XBIO stock exchanged was 13.36 million, exceeding the daily volume of 9.1 million for the past 50 days and exceeding the volume for the year to date of 3.46 million.

    XBIO stock has been declining 170.94% for the last 12 months, but has been gaining 80.11% for the past week. The XBIO stock has increased by 18.28% over the past six months, and it has increased by 49.53% over the past three months. XBIO stock is up 55.39% this year. After the private placement which was more expensive than the market, XBIO stock slumped.

    What was that private placement?

    As a biopharmaceutical company, Xenetic Biosciences, Inc. is working on XCART, a personalized CAR T platform engineered to identify patient- and tumor-specific neoantigens. In its initial research, XBIO is advancing cell-free therapeutics that target malignant B-cells on individual patients’ tumor cells for the treatment of B-cell lymphomas. A pipeline of therapeutic assets targeting oncology indications with high value can be generated by XCART.

    A healthcare-focused institutional investor has entered a definitive agreement with Xenetic Biosciences, the company announced on Monday.

    • XBIO has entered into a private placement priced at the market price of $2.70 per share to sell 4,629,630 shares of its common stock (or common stock equivalents).
    • In addition, XBIO has also agreed to issue warrants for the purchase of up to 4,628,630 shares of common stock to the investor.
    • Exercise price of the warrant to buy 4,629,630 shares of XBIO common stock is $3.30 per share.
    • When the US Securities and Exchange Commission declare the registration statement for resale of the shares of common stock issuing on exercise of the warrants as effective, the warrants will be immediately exercisable and expire three and a half years later.
    • XBIO anticipates closing the offering by July 28, 2021, assuming all customary closing conditions are satisfied.
    • The placement agent for XBIO’s offering was H.C. Wainwright & Co.

    What is likely to be the net proceeds for XBIO Stock?

    Xenetic (XBIO) is expected to receive approximately $12.5 million gross proceeds from the offering before deducting placement agent fees. A fully exercised set of warrants would generate approximately $15.3 million in gross proceeds. Net proceeds from the offering will be used to support XBIO’s general working capital needs.

  • Why Xenetic Biosciences Inc. (XBIO) stock is surging in the Monday’s pre-market??

    Xenetic Biosciences Inc. (XBIO) stock surged 24.21% in Monday’s pre-market as of this writing. In the regular trading session on Friday, XBIO’s stock gained 35.48%. XBIO shares have risen 108.26% over the last 12 months, and they have moved up 42.37% in the past week. Over the past three months, the stock has gained 29.90%, while over the past six months, it has shed 4.18%. Further, the company has a current market of $16.30 million and its outstanding shares stood at 8.75 million.

    Recent XBIO financial results announcement

    On May 12, 2021, Xenetic Biosciences, Inc reported its financial results for the first quarter of 2021.

    Q1 2021 financial highlights

    • The company suffered a net loss of approximately $1.3 million in Q1 2021
    • Research & development expenses were $0.6 million compared to $0.4 million in the comparable quarter in 2020.
    • General and administrative expenses were$0.9 million in Q1 2021 which were the same in Q1 2020.

    XBIO Participation in the recent investor conference

    Xenetic Biosciences recently participated at Q2 Virtual Investor Summit which was held on Tuesday, May 18, 2021. The company was presented by Chief Executive Officer Jeffrey Eisenberg presented the company during the event.

    Commencing Exploratory Study of XCART

    On March 29, 2021, Xenetic Biosciences, Inc received approval to commence its exploratory patient biopsy study in Eastern Europe evaluating XCART.

    The study will be conducted at the Vitebsk Regional Clinical Oncological Center in Minsk, Belarus, and will enrol adult B-Cell NHL patients. The collaborations being leveraged in the XCART development program may be expanded to include the development and qualification of manufacturing processes for producing autologous XCART T-Cells. The work being performed under these collaborations is expected to position the Company to conduct IND-enabling studies in the United States.

    XBIO Q4 & FY 2020 financial results

    On March 17, 2021, Xenetic Biosciences, Inc announced its financial results for the fourth quarter and full-year 2020.

    FY 2020 financial highlights

    • The company suffered a net loss of approximately $10.9 million in FY 2020.
    • For FY 2020, R&D expenses were $1.7 million compared to $4.9 million for the year ended December 31, 2019.
    • General and administrative expenses were $3.4 million from $4.7 million in the comparable period in 2019.
    • Working capital was approximately $11.4 million in FY 2020 compared to $9.7 million on December 31, 2019.
    • The Company ended the year with approximately $11.5 million of cash.

    Conclusion

    The recent Monday pre-market and Friday surge of XBIO stock has no grounds. There is no recent news or development which could be linked with Friday’s performance. We hope that it will commence the new week in a positive mode.